Clomipramine — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Obsessive-Compulsive Disorder

• Fluoxetine
• Fluvoxamine
• Paroxetine
• Sertraline

Other medications in Mental Health

• Clonazepam
• Clonidine
• Clorazepate
• Clozapine
• Desipramine
• Desvenlafaxine
• Dextroamphetamine
• Disulfiram

About Clomipramine

Clomipramine is a powerful medication primarily prescribed to manage Obsessive-Compulsive Disorder (OCD), offering a path to greater control over intrusive thoughts and compulsive behaviors. Understanding its role and how to access it affordably is crucial. Clomipramine, often recognized by its brand name Anafranil, is a tricyclic antidepressant (TCA) that has been a cornerstone in the treatment of Obsessive-Compulsive Disorder (OCD) for decades. While it belongs to an older class of antidepressants, its specific mechanism makes it particularly effective for OCD symptoms, often when other treatments have not fully succeeded. ### What Clomipramine Treats

Its primary indication is the treatment of Obsessive-Compulsive Disorder (OCD) in adults and children aged 10 and older. OCD is characterized by persistent, unwanted thoughts (obsessions) and repetitive behaviors (compulsions) performed to alleviate anxiety. Clomipramine helps to reduce the frequency and intensity of these obsessions and compulsions, allowing individuals to regain control over their daily lives. Beyond OCD, clomipramine may also be used off-label for other conditions such as panic disorder, chronic pain, and certain anxiety disorders, always under the careful guidance of a healthcare professional. ### How Clomipramine Works

Clomipramine works by affecting the balance of neurotransmitters in the brain, particularly serotonin and norepinephrine. As a TCA, it blocks the reuptake of these chemicals, leading to increased levels in the synaptic cleft. This enhanced availability of serotonin is believed to play a significant role in its anti-OCD effects, helping to regulate mood, reduce anxiety, and diminish obsessive thoughts and compulsive urges. Like many psychiatric medications, it takes time for clomipramine to reach its full therapeutic effect, with patients often noticing improvements over several weeks. ### Understanding Typical Costs

Without insurance, the cost of prescription medications like clomipramine can be a significant barrier. A month's supply of generic clomipramine can range from tens to hundreds of dollars, depending on the dosage, pharmacy, and whether you're purchasing the generic or brand-name version. Brand-name Anafranil is typically much more expensive. These costs can add up quickly, creating financial strain for those who rely on the medication for long-term management of their condition. That's right – no out-of-pocket cost for your medication! We believe that

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Clomipramine is approved for (FDA label)

Clomipramine Hydrochloride capsules, USP is indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD). The obsessions or compulsions must cause marked distress, be time-consuming, or significantly interfere with social or occupational functioning, in order to meet the DSM-III-R (circa 1989) diagnosis of OCD. Obsessions are recurrent, persistent ideas, thoughts, images, or impulses that are egodystonic. Compulsions are repetitive, purposeful, and intentional behaviors performed in response to an obsession or in a stereotyped fashion, and are recognized by the person as excessive or unreasonable.

Source: Read the full FDA label on DailyMed. Label effective date: December 26, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Clomipramine (FDA label)

Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of clomipramine hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressant compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality , or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Clomipramine hydrochloride is not approved for use in pediatric patients except for patients with obsessive compulsive disorder (OCD) ( see WARNINGS, Clinical Worsening and Suicide Risk ; PRECAUTIONS, Information for Patients ; and PRECAUTIONS, Pediatric Use ).

Source: FDA prescribing information (DailyMed). Set ID: fa0d4de8-c96e-429d-a65c-928afbf46863. SPL document ID: 48996a58-a312-4a01-ba38-0261a18bec65. Label effective date: December 26, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Clomipramine (FDA label)

Commonly Observed The most commonly observed adverse events associated with the use of Clomipramine hydrochloride capsules, USP and not seen at an equivalent incidence among placebo-treated patients were gastrointestinal complaints, including dry mouth, constipation, nausea, dyspepsia, and anorexia; nervous system complaints, including somnolence, tremor, dizziness, nervousness, and myoclonus; genitourinary complaints, including changed libido, ejaculatory failure, impotence, and micturition disorder; and other miscellaneous complaints, including fatigue, sweating, increased appetite, weight gain, and visual changes. Leading to Discontinuation of Treatment Approximately 20% of 3616 patients who received Clomipramine hydrochloride capsules, USP in U.S. premarketing clinical trials discontinued treatment because of an adverse event.

Source: FDA prescribing information (DailyMed). Set ID: fa0d4de8-c96e-429d-a65c-928afbf46863. SPL document ID: 48996a58-a312-4a01-ba38-0261a18bec65. Label effective date: December 26, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Clomipramine (FDA label)

Clomipramine hydrochloride capsule, USP is contraindicated in patients with a history of hypersensitivity to Clomipramine hydrochloride or other tricyclic antidepressants. Monoamine Oxidase Inhibitors (MAOIs) The use of MAOIs intended to treat psychiatric disorders with Clomipramine hydrochloride capsules, USP or within 14 days of stopping treatment with Clomipramine hydrochloride is contraindicated because of an increased risk of serotonin syndrome. The use of Clomipramine hydrochloride capsules, USP within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated ( see WARNINGS and DOSAGE AND ADMINISTRATION ). Starting Clomipramine hydrochloride capsules, USP in a patient who is being treated with linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome ( see WARNINGS and DOSAGE AND ADMINISTRATION ). Myocardial Infarction Clomipramine hydrochloride capsules, USP is contraindicated during the acute recovery period after a myocardial infarction.

Source: FDA prescribing information (DailyMed). Set ID: fa0d4de8-c96e-429d-a65c-928afbf46863. SPL document ID: 48996a58-a312-4a01-ba38-0261a18bec65. Label effective date: December 26, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Clomipramine (FDA label)

The risks of using Clomipramine hydrochloride capsules, USP in combination with other drugs have not been systematically evaluated. Given the primary CNS effects of Clomipramine hydrochloride capsules, USP, caution is advised in using it concomitantly with other CNS-active drugs ( see Information for Patients ). Clomipramine hydrochloride capsules, USP should not be used with MAO inhibitors ( see CONTRAINDICATIONS ). Close supervision and careful adjustment of dosage are required when Clomipramine hydrochloride capsules, USP is administered with anticholinergic or sympathomimetic drugs. Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.

Source: FDA prescribing information (DailyMed). Set ID: fa0d4de8-c96e-429d-a65c-928afbf46863. SPL document ID: 48996a58-a312-4a01-ba38-0261a18bec65. Label effective date: December 26, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.